E Psychedelic Stocks Index: +58.4% In December

TM Editors Note: Many of the companies mentioned in this article are penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

This article tracks the performance of 15 of the 31 biopharmaceutical companies involved in the research and development of psychedelic compounds to treat mental health issues such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders in the munKNEE Pure-Play Psychedelic Stocks Index.

Index Inclusion Criteria

The 15 stocks eligible for inclusion in the index are based on the following criteria:

  • a market capitalization between US$10M and US$200M
  • a stock that trades between US$0.10/share and US$2/share

Below are the 15 eligible companies in the munKNEE Pure-Play Psychedelic Stocks Index and their performance for the month of December in alphabetical order with their performance in November in brackets. [Ed. note: Keep in mind that percentages for tiny-caps can often only reflect changes counted in cents.]

  1. Better Plant (VEGGF) +116.7% (+20.0%)
  2. Champignon (SHRMF) +34.8% (+34.8%)
  3. Cybin (CLXPF) +120.6% (+750.0%)
  4. Havn (HAVLF) +20.3% (-4.5%)
  5. Hollister (HSTRF) +122.2% (N/C)
  6. Jaguar (JAGX) +131.4% (+75.0%)
  7. Mind Cure (MCURF) +14.0% (-12.5%)
  8. Mydecine (MYCOF) +45.8% (+60.0%)
  9. Nova Mentis (LIBFF) -15.0% (+53.8%)
  10. Numinus (LKYSF) +55.6% (+68.8%)
  11. Psyched Wellness (DCNPF+15.8% (+850.0%)
  12. Red Light (TRUFF+166.7% (+50.0%)
  13. Revive (RVVTF) +118.2% (+46.7%)
  14. Seelos (SEEL+61.2% (+32.4%)
  15. Silo Pharma (SILO) +10.5% (+90.0%)

The above 15 psychedelic drug stocks increased, on average, by 58.4% in December and 48.7% in November (+135.4% over that 2-month period).

When "big pharma" realizes the potential of psychedelics in treating mental health issues many of the companies identified in this article will be bought out and those that remain should see their stock prices continue to undergo major appreciation. Do your own due diligence and determine if any of these stocks belong in your portfolio.

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.